Evidence map›Paper›PMID 41850237›Full record

ArticleCell reports. Medicine2026

FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Xudong Li, Shiyu Zuo, Yanli Zhang, Zexing Liu, Na Shen, Qingqing Ma, Mingxia Sun, Binglei Zhang, Mengjia Li, Hong Huang and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Xudong LiDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China; Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shiyu ZuoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yanli ZhangDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Zexing LiuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Na ShenDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qingqing MaDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mingxia SunSchool of Public Health, Zhengzhou University, Zhengzhou, Henan 450000, China.
Binglei ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mengjia LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hong HuangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mengya GaoDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China; Department of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Zhenghua HuangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Huifang ZhaoDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Yilin ChenDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Fengcai GaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Wenjuan FanDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhen ZhangDepartment of Abdominal and Pelvic Tumor Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China.
Yuhan HuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yu AnDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Siyue LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Miao LiuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Yupeng LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yuxuan LiuDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chaoge LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yiguo ZhangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yingmei LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Weijie CaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Fang WangDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yongping SongDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Electronic address: songyp@zzu.edu.cn.
Linping XuDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China. Electronic address: zlyyxulinping1475@zzu.edu.cn.
Zhilei BianDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Zhengzhou, China. Electronic address: bianzhilei@zzu.edu.cn.
Wei LiDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Zhengzhou, China. Electronic address: zlyylw3028@zzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eradicating leukemia stem cells (LSCs) and overcoming tyrosine kinase inhibitor (TKI) resistance is urgent for chronic myeloid leukemia (CML) treatment. We find that F-box protein 3 (FBXO3) is highly upregulated in CD34

Indexed as

Drug Resistance, NeoplasmF-Box ProteinsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsProtein Kinase InhibitorsSKP Cullin F-Box Protein LigasesAnimalsApoptosisCell Line, TumorCell ProliferationHumansImatinib MesylateMiceUbiquitinationF-Box ProteinsImatinib MesylateProtein Kinase InhibitorsSKP Cullin F-Box Protein Ligaseschronic myeloid leukemiaCML-LSCsDUSP9FBXO3TKI resistance

Identifiers

PMID41850237
PMCPMC13006436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.